Year: 2020
Type: article
Abstract: During this last year, there has been much progress with regard to anticoagulant and ablation therapy for atrial fibrillation (AF). Apart from recently issued European Society of Cardiology Guidelines for the management of patients with supraventricular arrhythmias, there has been little progress in research in this field. Ventricular arrhythmias and device therapy have seen modest progress. This year has seen several publications on the ECG diagnosis of supraventricular tachycardia (SVT)1–4 and interest in new consumer-led discovery of supraventricular arrhythmias.5 EP mapping technology has provided better mapping of SVT.6 There has been a surprising interest in new antiarrhythmic drugs for SVT, ranging for intranasal etripamil (an L-type calcium antagonist) for termination of SVT7,8 and nifekalant to increase the refractoriness of accessory pathways and reduce the rate of pre-excited supraventricular arrhythmias.9 2019 saw new European Society of Cardiology guidelines for the management of patients with SVT10 which had previously been in 2003. However, there was little which was very new. The guidelines insisted that ablation was the best initial management for most re-entrant atrial and AV junctional tachycardia. However atrial tachycardia occurring after ablation for AF should not be considered for ablation until at least 3 months after the AF ablation procedure. The guidelines stressed that ablation for AV nodal re-entrant tachycardia could be achieved in almost all without risk of AV block. An invasive EP risk assessment of Wolff–Parkinson–White syndrome was recommended even in patients who are asymptomatic but have high-risk occupations or are competitive athletes. The guidelines recommend ablation in high risk or symptomatic WPW patients but stop short of recommending ablation of all accessory pathways. It is pointed out that SVT may cause tachycardia mediated cardiomyopathy and that ablation may not only eliminate the tachycardia but restore ventricular function. There are strong Class III recommendations—‘what not to do’, mostly related to antiarrhythmic drug therapy (Figure 1). Some ‘What not to do’ recommendations from the 2019 ESC Guidelines on the management of patients with supraventricular tachycardia. MRAT, macro re-entrant atrial tachycardia. Reproduced from Brugada et al.10 Some ‘What not to do’ recommendations from the 2019 ESC Guidelines on the management of patients with supraventricular tachycardia. MRAT, macro re-entrant atrial tachycardia. Reproduced from Brugada et al.10 Various studies have highlighted new developments in the risk assessment for the development of AF and its complications, as well as the use of the non-vitamin K antagonist oral anticoagulants (NOACs) as thromboprophylaxis. Numerous clinical factors associated with incident AF have been described11 but a simple, practical and reliable approach to identifying patients at risk of incident AF is needed. Clinical factors such as change in body mass index have been associated with an increased risk of AF,12 as has disordered sleep pattern.13 Various clinical risk scores for identifying incident AF have been described, and as with most clinical scores, all have modest predictive value for identifying high-risk patients and until recently, have been complex models derived from multivariate analyses. The C2HEST score was derived and validated in Asia and has recently been externally validated in a French post-stroke cohort and the Danish nationwide registries.14,15 This would facilitate targeted intensive screening for AF, for example, in the post-stroke population with AF, where oral anticoagulation (OAC) as secondary prevention is well established. In contrast, two randomized trials in embolic stroke of unknown source (ESUS) using NOACs failed to show a significant reduction in recurrent stroke, while one trial (NAVIGATE-ESUS) showed an excess of bleeds.16,17 Screening for AF has attracted much attention, with population-based approaches and new technologies.18 The Apple Watch study investigated if a smartwatch-based irregular pulse notification algorithm identified possible AF, and reported that among participants who received notification of an irregular pulse, 34% had atrial fibrillation AF on subsequent ECG patch readings and 84% of notifications were concordant with AF.19 The Huawei Heart Study also showed the usefulness of photoplethysmographic (PPG) -based technology in population screening for AF, with the positive predictive value of PPG signals being 91.6% and leading to improved anticoagulation use (>80%).20 Risk assessment continues to evolve, with availability of new data showing stroke risks associated with AF patients with hypertrophic cardiomyopathy21 and imaging-documented significant coronary artery lesions.22 There has been much interest into use of sophisticated methods such as machine-learning, even predicting incident AF from a simple 12-lead ECG.23 More complex risk assessment approaches improve AF stroke risk prediction (at least statistically) but need to be balanced against simplicity and practical application. For now, an independent Patient Cantered Outcome Research Institute (PCORI)-sponsored systematic review and evidence appraisal identified that amongst the commonly used risk stratification schemes in patients with AF, the CHA2DS2VASc and HAS-BLED scores were the best predictors for stroke and bleeding risks, respectively.24 Bleeding risk prediction only focused on modifiable bleeding risk factors is an inferior strategy to a formal risk assessment using the HAS-BLED score.25,26 Stroke and bleeding risk assessments incorporating biomarkers have been proposed based on highly selected anticoagulated clinical trial cohorts but ‘real-world’ studies have not shown the usefulness of such schemes. One study showing sequential addition of biomarkers did not improve the usefulness of stroke and bleeding risk prediction.27 Also, there are no data across the patient pathway, when first diagnosed and non-anticoagulated, or on aspirin—and following the initiation of OAC. Of note, many risk factors are based on baseline risk assessment but do not remain static and changes with age and incident risk factors.25,28 Thus, AF assessment is not a ‘one off’ item and needs to be reassessed at regular intervals, e.g. every 4–6 months.29 The NOACs have changed the landscape of stroke prevention in AF. These drugs are now the preferred OAC option in most guidelines, but challenges remain in its use amongst high-risk subgroups that were under-represented in clinical trials, as well as its adherence and persistence. Clinical trial cohorts are selected populations and may be at lower risk compared to ‘real-world’ clinical practice data.30 The year also saw the first publications of real-world data for edoxaban, which was the fourth NOAC to enter the market.31 Increasing data for the NOACs in the elderly have been published,32,33 clearly showing their effectiveness and safety even in very elderly subjects, aged ≥80. Additional data emphasize the importance of using the appropriate label-adherent dosing to ensure best outcomes, as well as persistence data with the NOACs, for example, with dabigatran.34 One trial, AEGEAN showed high adherence and persistence with apixaban (∼90%) but did not show additional benefit from interventions to improve adherence/persistence.35 Also, studies of NOAC use in extremes of renal function, both severe renal impairment and supra-normal renal function. The latter is pertinent given that all three Factor Xa inhibitors showed numerically more ischaemic strokes in the subgroup with CrCl >95 mL/min when compared with warfarin in their pivotal trials, although this is not apparent in real-world observational data.36 In end-stage renal failure, observational data show better safety for apixaban over warfarin.37 The last year has seen new trials with NOACs in catheter ablation (CA) for AF, and in the setting of AF patients presenting with an ACS or undergoing PCI/stenting. For CA, an uninterrupted NOAC-based strategy appears to be a safer option compared to a warfarin-based strategy.38–40 In AF/ACS/PCI patients, the publication to AUGUSTUS and ENTRUST-AF PCI completes the trials of NOACs in this clinical setting.41,42 These trials suggest that when OAC is used, a NOAC-based regime or a dual therapy (i.e. OAC plus a P2Y12 inhibitor) is associated with less major bleeding.43 Of the overall thrombotic or ischaemic outcomes, there is little difference between a triple therapy or dual therapy approach, or a NOAC-based strategy compared to a warfarin-based strategy. However, a dual therapy approach may be associated with an excess of stent thrombosis and myocardial ischaemic events, thus patients who are at high risk of such outcomes may merit a short period of triple therapy at the start. In stable coronary disease, OAC alone is associated with better outcomes compared to dual therapy, in the AFIRE trial.44 While the concept of integrated AF management has been proposed, its application and implementation in a simple user-friendly manner have not been previously validated. Integrated care has been associated with reduced mortality and hospitalization.46 One integrated and holistic approach to AF management, streamlining the decision-making management approaches that would be uniformly applicable across the whole AF patient pathway, starting with primary care and linking with secondary care (including cardiologist/non-cardiologists), and understandable for the AF patients per se, is the ABC (Atrial fibrillation Better Care) pathway: Avoid stroke; Better symptom management with patient-centred symptom directed decisions on rate or rhythm control; Cardiovascular and risk factor optimisation, including lifestyle changes45 (Figure 2). The ABC pathway approach has now been shown in independent studies to be associated with a reduction in mortality, hospitalization and adverse outcomes, as well as reduced healthcare costs, when compared to ‘non-ABC’ adherent management.47–50 The ABC pathway was tested in a cluster randomized trial showing improved clinical outcomes with an ABC pathway management based on an interactive App that included risk assessments, patient decision aids, educational materials and dynamic tracking of risk (mAFA-II trial20; presented as Late Breaking Science at the ESC congress, September 2019). Managing atrial fibrillation–Easy as ABC. Managing atrial fibrillation–Easy as ABC. A number of publications have described AF CA outcomes and impact on prognosis. Probably the most eagerly awaited was the CABANA study.51 This multicentre study randomized 2204 patients to CA or drug therapy. As designed, intention to treat, the study was neutral for CA impacting on the primary composite endpoint of death, disabling stroke, serious bleeding, or cardiac arrest. This type of study is incredibly difficult to recruit for because the clinicians most likely to recruit are seeing a patient referred for a CA, so even if they are prepared to enter the study, the cross-over rate is likely to be high from drug to ablation, as it was in this study (27.5%). When analysing by treatment, there was a prognostic benefit, but this subverts the principle of randomization and increases bias. The cerebral micro-emboli associated with AF CA do not appear to have much impact and CA itself may improve cognitive impairment as in 308 patients studied and followed for 1 year.52 Most electrophysiologists continue to tell patients that the primary goal of AF ablation is quality of life (QOL). The first randomized controlled trials (RCT) of AF CA vs drugs to examine QOL as the primary endpoint was published in 2019 and favoured CA.53 While this was a small study, 155 patients, it does open the way for double-blind RCTs of AF CA with QOL as the primary outcome. The use of cryoablation for AF has accumulated more evidence this year: it is faster than RF CA,54 associated with lower risk of pericardial effusion,55,56 and has superior outcomes54,55 regardless of centre volume.57 Several large registries have published this year. The Swedish registry reveals CA procedure complications and death were low and that AF, ventricular tachycardia (VT), and premature ventricular complex (PVC) CA numbers increased with AF having the highest repeat procedure rate (41%).58 A European registry demonstrated that cryoablation is as effective for female patients but is associated with higher complication rates.59 The Danish registry confirmed that success rates for AFL ablation were 90% but that AF is a common presentation (13%) within 2 years after.60 The German Helios registry showed that pericardial effusion rates were 0.9% in 21 141 AF CA, and was more likely in low volume centres, but only if RF was used rather than cryo.55 CA of VF storm after myocardial infarction was reported in a multicentre study of 110 patients.61 In-hospital mortality (27%) and 2-year follow-up mortality (36%) were high and associated with the time taken to perform CA. A retrospective study of 110 patients demonstrated CA of recurrent VT in patients with arrhythmogenic ventricular cardiomyopathy is no more effective than drugs but is more likely to be successful if both epicardial and endocardial approaches are used.62 It is recognized that the primary reasons for failure of CA in complex arrhythmia are a lack of understanding of the mechanism. There continues to be huge effort to solve this. This year ripple mapping has been used successfully used in persistent AF (18 months 53% vs. 39% conventional),64 atrial tachycardia,65 and VT in arrhythmogenic right ventricular cardiomyopathy (ARVC).66 Non-contact mapping is returning to clinical practice with an observational trial showed good outcomes for persistent AF CA at 12 months (59%).67 The STAR mapping system (Figure 3), presented its feasibility clinical trial of 35 patients showing freedom from AF after persistent AF CA guided by STAR of 80% at 18 months.68 It remains to be seen whether any of these make it to widespread clinical use. Ai- STAR map in an anterior-posterior view that shows an ESA (highlighted by the number 1) mapped to the anterior wall at the base of the LA appendage. Aii- Ablation here as demonstrated on a CARTO map in an anterior-posterior view resulted in Aiii- AF cycle length slowing from 152ms to 193ms as measured from the LA appendage electrograms. Further cluster lesions at this ESA also intermittently organised CS activation. Bi- STAR map in a tilted posterior-anterior view that shows a further ESA (highlighted by the number 2) mapped to the posterior-inferior wall. Bii- Ablation here as shown on the CARTO maps in a similar view resulted in Biii- AF termination to AT as shown on the intracardiac electrograms. The AT was mapped to a mitral isthmus dependent flutter which was successfully ablated to sinus rhythm. Ai- STAR map in an anterior-posterior view that shows an ESA (highlighted by the number 1) mapped to the anterior wall at the base of the LA appendage. Aii- Ablation here as demonstrated on a CARTO map in an anterior-posterior view resulted in Aiii- AF cycle length slowing from 152ms to 193ms as measured from the LA appendage electrograms. Further cluster lesions at this ESA also intermittently organised CS activation. Bi- STAR map in a tilted posterior-anterior view that shows a further ESA (highlighted by the number 2) mapped to the posterior-inferior wall. Bii- Ablation here as shown on the CARTO maps in a similar view resulted in Biii- AF termination to AT as shown on the intracardiac electrograms. The AT was mapped to a mitral isthmus dependent flutter which was successfully ablated to sinus rhythm. High power short-duration RF may make point-by-point AF CA faster and, at least so far, not being associated with worse outcomes.63 Electroporation is also showing promise as a novel energy source that is highly effective with low complication rates.69 The use of radiotherapy to treat intractable VT is an exciting innovation, showing promising results in a small prospective study of 19 patients.70 A number of guidelines have been published this year and while these are useful reviews of the literature, the temptation to accept them as dogma has to be resisted given that they are often drive by consensus of a well-intentioned writing group rather than hard data. CA of ventricular arrhythmia (VA) guideline suggests that programmed electrical stimulation may come back into fashion as a method for prognostic prediction, this time in patients with frequent PVCs and structural disease, and also use of for ablation although much of the does not use without any apparent to their The in arrhythmia consensus highlighted that although outcomes may be this should not of CA for This has been an exciting year in arrhythmogenic cardiomyopathy There are major publications to be The first is the Heart Society on This which was by and as a that with symptomatic asymptomatic arrhythmias in with of cardiac This approach the more recently described arrhythmogenic ventricular as well as subgroups of within are disease, and a large number of This is a and that is to be One of the writing was to having patients with arrhythmias and a cardiomyopathy to a centre that perform for and a risk and need for an publication was by et the of an risk was to risk and decisions More than patients from registries in and were During years of death, or received an appropriate therapy. A prediction to risk was (Figure The at baseline included in the are the number of PVCs in and right ventricular a by et investigated the value of an in An to was identified in and cohorts and The was in and The that are a and for this be used it need to be tested in more populations including with cardiac of ventricular arrhythmia in arrhythmogenic right ventricular arrhythmogenic right ventricular premature ventricular right ventricular ventricular of ventricular arrhythmia in arrhythmogenic right ventricular arrhythmogenic right ventricular premature ventricular right ventricular ventricular et the use of among patients who out of cardiac in More than of cardiac in increased between and from to 84% in and from to in the increased use of resulted in an increased from to for in and from to in is the evidence guideline recommendations for primary prevention in and patient and in failure, trials well over a be to clinical (Figure to a large from the death to failure remains the leading cause of death for the of evidence ventricular as a or arrhythmogenic leading to cardiac death which may be reduced by at even these and cardiac therapy These and into the of the randomized clinical trial evidence recommendations for primary prevention in failure a they the if trials should come with a after which they would the device have over the last including better to ventricular arrhythmias and to as well as the development of such as the and the even appear to be and effective in the large these novel come with a reduced which may the as well as remain the most complications of which come with a impact on quality of and mortality and for patients with to Heart and are a of and risk and are not evidence that for patients in Heart Class interventions for death may be or to to a of life because the patient is likely to of death, death to myocardial infarction and stroke; that are more likely to be as failure mortality and for patients with to Heart and are a of and risk and are not evidence that for patients in Heart Class interventions for death may be or to to a of life because the patient is likely to of death, death to myocardial infarction and stroke; that are more likely to be as failure In better of risk prediction for and ventricular are in to better patients who need it who do not from device One such risk prediction for patients infarction with has recently been using risk factors increased reduced rate and with with programmed ventricular The algorithm an and predictive value the most of as well as a of on the positive predictive value was only such as may further value in identifying patients at increased risk of ventricular arrhythmias who may benefit from are being also for such as arrhythmogenic right ventricular cardiomyopathy positive in randomized clinical trials, these may the to the of for risk such trials are it may be to to the evidence and guideline at the into trials is in to the of evidence which may clinical therapy remains an for failure patients to and to improve and However, the rate of remains in the of on and The trial investigated the of the from two of one to reduce the number of and patients as as an volume reduction by months after were randomized to the algorithm on or of care While the rate to was no between the two vs. patients in the group programmed to a were more likely to to than programmed to vs. and these have to be as in view of the primary of has received and from and and from and is a for and for and are received from and from and from and from and from the of the and from from the In has a STAR mapping has received and or from and of from from from from from the has received from and The in this are not of the of the European Heart or of the European Society of
Source: European Heart Journal
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2999827648